Where does Helix Biopharma Corp. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Helix Biopharma Corp. ranks #26,460 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Helix Biopharma Corp. hold?

Helix Biopharma Corp. holds 10 US utility patents granted between 2015 and 2024, spanning 7 technology areas.

What is Helix Biopharma Corp.'s Innovation Score?

Helix Biopharma Corp. has an Innovation Score of 36.8 out of 100 (top 45% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Helix Biopharma Corp.'s patent grant rate increasing or decreasing?

Helix Biopharma Corp.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Helix Biopharma Corp.'s patents?

Helix Biopharma Corp.'s patents average 15.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Helix Biopharma Corp. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Helix Biopharma Corp.

Q: What technology areas does Helix Biopharma Corp. focus on?

Helix Biopharma Corp.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 10 patents. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Helix ranks #26,460 of 50,000 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#26,460
of 50,000 US assignees by volume: Top 45%
by Innovation Score (36.8/100): 15.3
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26460 · Foreign Corporation #26,460 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,460/50,000
PHOTO-FINISH HealthStream
CPC-NARROW A61P · 7 areas
INNOV-THIN 36.8/100
CLAIMS-RICH 15.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Healthstream, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Helix Biopharma · this assignee

37
3D Lighting Innovati… · lowest

7

What this shows Helix's Innovation Score is 36.8/100 (top 45% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Helix's grants concentrate

Helix Biopharma Corp. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2016. By volume, Helix sits between Healthstream, Inc. and Hinsey's Pro Paint, Inc..

Helix's three-year grant acceleration

Helix Biopharma Corp. shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Healthstream

10
Hearth Hounds

10
Heatworks

10
Heinrich-heine-un…

10
Heraeus Nexensos

10
Hibercell

10
Hillstone Networks

10
Hinsey's Pro Paint

10
Helix Biopharma ◀

10

What this shows Helix holds 10 patents at rank #26,482, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Helix

By rank, the assignees closest to #26,482 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Helix's primary technology class.

Helix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 45% higher than 55% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Helix Biopharma Corp. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	40.0%
2016	1	10.0%
2019	1	10.0%
2020	1	10.0%
2022	1	10.0%
2024	2	20.0%

Which technologies does Helix Biopharma Corp. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 10

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 10

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 5

C07K - PEPTIDES 4

C12Y - ENZYMES 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#26,460

of 50,000 tracked assignees

Innovation Score

36.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.